Overview

A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy

Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
0
Participant gender:
All
Summary
This is one of two replicate randomized, double-blind, placebo-controlled, parallel arm trials to determine the safety and efficacy of two different dose levels of SEL-212 compared to placebo. Approximately 105 patients, stratified as to the presence or absence of tophi, will be randomized in a 1:1:1 allocation ratio prior to Baseline to receive treatment with one of two dose levels of SEL-212 or placebo every 28 days for approximately 6 months in each trial (SEL-212/301 and SEL-212/302). Analysis of efficacy will be performed at Day 28 of Treatment Period 6. Safety will be monitored throughout the study.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Selecta Biosciences, Inc.
Criteria
Inclusion Criteria:

1. Has negative results of an FDA Emergency Use Authorized COVID-19 molecular assay for
detection of SARS-CoV-2 RNA from a respiratory specimen;

2. History of symptomatic gout defined as:

1. ≥ 3 gout flares within 18 months of Screening or

2. Presence of ≥ 1 gout tophus or

3. Current diagnosis of gouty arthritis

3. At the Screening Visit: male age 21 - 80 years, inclusive, or female of
non-childbearing potential age 21-80 years, inclusive, where nonchildbearing potential
is defined as:

a. > 6 weeks after hysterectomy with or without surgical bilateral salpingooperhectony
or b. Post-menopausal (> 24 months of natural amenorrhea or in the absence of >24
months of amenorrhea, one documented confirmatory FSH measurement)

4. Has chronic refractory gout defined as having failed to normalize sUA and whose signs
and symptoms are inadequately controlled with any of the xanthine oxidase inhibitors,
or for whom these drugs are contraindicated for the patient;

5. Has at the Screening Visit SUA ≥ 7 mg/dL

6. Negative serology for HIV-1/-2 and negative antigen to hepatitis B and negative
antibodies to hepatitis C;

Exclusion Criteria:

1. Has a history of anaphylaxis, severe allergic reactions, or severe atopy;

2. Has a history of any allergy to pegylated products, including, but not limited to
pegloticase (Krystexxa®), peginterferon alfa-2a (Pegasys®), peginterferon alfa-2b
(PegIntron®), pegfilgrastim (Neulasta®), pegaptanib (Macugen®), pegaspargase
(Oncaspar®), pegademase (Adagen®), peg-epoetin beta (Mircera®), pegvisomant
(Somavert®) certolizumab pegol (Cimzia®), naloxegol (Movantik®), peginesatide
(Omontys®), and doxorubicin liposome (Doxil®);

3. Is taking and cannot discontinue known major CYP3A4/P-gp inhibitors or major
CYP3A4/P-gp inducers at least 14 days before dosing. Patients must remain off these
medications for the duration of the study, including natural products such as St.
John's Wort or grapefruit juice.

4. Is taking drugs known to interact with rapamycin (sirolimus - Rapamune®) such as
cyclosporine, diltiazem, erythromycin, ketoconazole, posaconazole, voriconazole,
itraconazole, rifampin, verapamil unless they are stopped 14 days prior to dosing and
will not be used/prescribed during the trial.

5. Is a post-menopausal woman that has initiated or had a change in dose of hormone
replacement therapy (HRT) less than 1 month prior to the Screening Visit or during the
Screening Phase.

6. Had a gout flare during Screening that was resolved for less than 1 week prior to
first treatment with study drug (exclusive of chronic synovitis/arthritis) unless the
patient has a history of inter-flare intervals of < 1 week.

7. Has uncontrolled diabetes at Screening with HbA1c ≥ 8.5%;

8. Has fasting Screening glucose > 240 mg/dL;

9. Has fasting Screening triglyceride > 500 mg/dL;

10. Has fasting Screening low-density lipoprotein (LDL) > 200 mg/dL;

11. Has glucose-6-phosphate dehydrogenase (G6PD) deficiency;

12. Has uncontrolled hypertension defined as blood pressure > 170/100 mmHg at Screening
and 1 week prior to dosing

13. Individual laboratory values which are exclusionary

- White blood cell count (WBC) < 3.0 x109/L

- Serum aspartate aminotransferase (AST) or alanine amino transferase (ALT) > 3x
upper limit of normal (ULN) in the absence of known active liver disease

- Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2

- Urine albumin creatinine ratio (UACR) > 3.0

- Hemoglobin (Hgb) < 9 g/dL

- Serum phosphate < 2.0 mg/dL

14. Is receiving ongoing treatment for arrhythmia, including placement of an implantable
defibrillator, unless considered stable and on active treatment;

15. Has evidence of unstable cardiovascular disease or unstable cerebrovascular vascular
disease. This includes patients who have had a cardiac/vascular event(s) in the last 3
months including heart attack, stroke or vascular bypass surgery or patients who are
deemed, by their physician or PI, to have active cardiovascular, cerebrovascular or
peripheral vascular symptoms/disease inadequately controlled by medication;

16. Has congestive heart failure, New York Heart Association Class III or IV;

17. Unless clinically stable and/or appropriately treated, electrocardiogram (ECG) with
evidence of clinically significant arrhythmia or other abnormalities that, in the
opinion of the investigator, are consistent with significant underlying cardiac
disease;

18. History of significant hematological disorders within 5 years or autoimmune disorders,
and/or patient is currently immunosuppressed or immunocompromised;

19. Prior exposure to any experimental or marketed uricase (e.g., rasburicase (Elitek,
Fasturtec), pegloticase (Krystexxa®®), pegadricase (SEL 037))

20. Patient has received a live vaccine in the previous 6 months.

21. Patient is planning to receive any live vaccine during the study.

22. History of malignancy within the last 5 years other than basal skin cancer;

23. Patients with a documented history of moderate or severe alcohol or substance use
disorder within the 12 months prior to randomization.

24. History of or evidence of clinically severe interstitial lung disease

25. Immunocompromised state, regardless of etiology